NCT07903181
Dynamic ctDNA Monitoring in Advanced Malignant Phyllodes Tumors of the Breast
StatusNot Yet Recruiting
PhaseNot specified
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Progression-Free Survival According to Early ctDNA Status Transition Patterns
Timeframe: From treatment-line initiation to radiologically confirmed progression, death, or censoring (up to 24 months); ctDNA at pretreatment baseline and before Cycle 3. Cycle length varies by regimen (usually 28 days; sometimes 21 days or other durations).
Secondary (6)
Progression-Free Survival According to Baseline ctDNA Detection Status
Progression-Free Survival According to Baseline ctDNA Concentration
Progression-Free Survival According to ctDNA Status Transitions Before Cycle 2
Progression-Free Survival According to the ctDNA Concentration Ratio at T1 Versus Baseline
Progression-Free Survival According to the ctDNA Concentration Ratio at T2 Versus Baseline
Show 1 moreShow less
Progression-Free Survival According to Time-Updated ctDNA Detection Status at Subsequent Imaging Visits
Arms and interventions
Advanced Malignant Phyllodes Tumor Cohort
Patients with advanced malignant phyllodes tumors of the breast who have distant metastases or are currently considered unsuitable for curative surgery and who are starting or receiving a current line of systemic therapy without a progression-free survival event at enrollment. Participants included in the primary longitudinal analysis must have a valid pretreatment blood sample obtained before the first dose of the current systemic treatment line. Participants will undergo longitudinal ctDNA monitoring, imaging assessment, and clinical follow-up during the current treatment line.
Sites
1 site in 1 country
- Sun Yat-Sen Memorial Hospital, Sun Yat-Sen UniversityGuangzhou, Guangdong, China